Vaginal morbidity and sexuality sub-study

The study on vaginal morbidity has started 2013 within EMBRACE I and will continue accrual within EMBRACE II. In a prospective longitudinal design, dosimetric and treatment parameter will be correlated with detailed information on vaginal morbidity (including 3-dimensional mapping of symptoms) and linked to patients’ reports on vaginal symptoms, sexual functioning and psychosocial impact. In addition, the impact of regular dilation on vaginal adhesions, length and width will be evaluated.

At 2017, around 100 patients have been included in the sub-study. Accrual finished in 2018.

Contact person:

Kathrin Kirchheiner (

Remi Nout (

Kari Tanderup (